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Infection with Cryptococcus neoformans begins when desiccated yeast cells or spores are inhaled and lodge in the alveoli of the
lungs. A subset of cryptococcal cells in the lungs differentiate into enlarged cells, referred to as titan cells. Titan cells can be as
large as 50 to 100 m in diameter and exhibit a number of features that may affect interactions with host immune defenses. To
characterize the effect of titan cell formation on the host-pathogen interaction, we utilized a previously described C. neoformans
mutant, the gpr4 gpr5 mutant, which has minimal titan cell production in vivo. The gpr4 gpr5 mutant strain had attenu-
ated virulence, a lower CFU, and reduced dissemination compared to the wild-type strain. Titan cell production by the wild-type
strain also resulted in increased eosinophil accumulation and decreased phagocytosis in the lungs compared to those with the
gpr4 gpr5 mutant strain. Phagocytosed cryptococcal cells exhibited less viability than nonphagocytosed cells, which poten-
tially explains the reduced cell survival and overall attenuation of virulence in the absence of titan cells. These data show that
titan cell formation is a novel virulence factor in C. neoformans that promotes establishment of the initial pulmonary infection
and plays a key role in disease progression.
Cryptococcus neoformans is an opportunistic fungal pathogenthat causes meningoencephalitis in severely immunocompro-
mised individuals, including people living with HIV/AIDS. Cur-
rent epidemiological estimates show that fatalities due to crypto-
coccosis exceed 650,000 each year in people with AIDS (37). In
sub-Saharan Africa, cryptococcosis has now surpassed tuberculo-
sis in terms of annual fatality rates (37). Thus, cryptococcosis is
emerging as a significant disease in immunocompromised popu-
lations worldwide, with particularly high burdens of disease in the
developing world, where access to quality medical care is limited.
The infectious particles are thought to be spores, although des-
iccated yeast cells are also small enough to be inhaled and then
lodge in the alveoli of the lungs (19). Upon inhalation into the
lungs, spores germinate to produce yeast cells that can establish
the initial pulmonary infection (5, 19). The pulmonary infection is
typically controlled or cleared in healthy individuals. However, in
immunocompromised individuals, the infection can disseminate
from the lungs, penetrate the blood-brain barrier, and result in
highly lethal meningitis (5, 19).
Several virulence factors, such as capsule and melanin, pro-
duced by C. neoformans during the infectious process, have been
shown to promote survival in the host. Capsule plays a critical role
in modulation of the host immune system through sequestration
of opsonins such as antibodies and complement C3, as well as by
induction of host phagocytic cell apoptosis (19, 26, 43). Acapsular
mutant strains are avirulent in animal models of cryptococcosis
(1, 6–10, 19). Protection from oxidative and nitrosative stresses
generated by host phagocytes and neutrophils is conferred by the
dark pigment melanin (19). Synthesis of melanin is regulated by
laccase (LAC) genes, and lac1 mutant strains have attenuated
virulence in animal models (19, 28, 31, 38–40). Additional viru-
lence factors, such as urease and hyaluronic acid production, af-
fect survival within macrophages or direct interactions with the
endothelial cells of the blood-brain barrier (22, 23, 35). Thus, C.
neoformans has evolved multiple strategies to evade host defenses
against infection.
A novel cell morphology was recently characterized for cryp-
tococcal pulmonary infections that may promote pulmonary sur-
vival and dissemination. Upon exposure to the pulmonary envi-
ronment, a subset of cryptococcal cells in the lungs produce
enlarged “titan” cells (33, 46). Approximately 10 to 20% of the
cryptococcal cells in the lungs transition to the titan cell pheno-
type and grow to be as large as 50 to 100 m in diameter, which is
5- to 10-fold larger than a typical cryptococcal cell (33).
Titan cells have several characteristics that differentiate them
from normal-size cells. First, titan cells have an altered capsule
structure which is highly cross-linked and cannot be sheared from
the cryptococcal cell by chemical or physical methods (46). Sec-
ond, the cell wall of titan cells is approximately 30- to 50-fold
thicker than the cell wall of normal-size cells, as seen by transmis-
sion electron microscopy (TEM) (46). Third, titan cells are resis-
tant to oxidative and nitrosative stresses similar to those employed
by phagocytes to kill pathogens (33, 46). Finally, titan cells are too
large to be phagocytosed by host immune cells in the lungs, and
the production of titan cells reduces phagocytosis of normal-size
cryptococcal cells (32). Taken together, these data show that titan
cells have characteristics that may promote survival in vivo.
The known characteristics of titan cells suggest that their pro-
duction could be important for cryptococcal virulence. To test
this hypothesis, we analyzed the survival and virulence of purified
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titan cells as well as mutant strains with altered titan cell produc-
tion. We show that titan cell production promotes survival in the
host and enhances cryptococcal virulence. These data show that
titan cell production is a virulence factor in C. neoformans.
MATERIALS AND METHODS
Animal experiments. All animals were handled in strict accordance with
good animal practice as defined by the relevant national and local animal
welfare bodies, i.e., (i) the University of Minnesota Institutional Animal
Care and Use Committee (IACUC), under protocol numbers 0712A22250
and 1010A91133; and (ii) the University of North Carolina-Chapel Hill
IACUC, under protocol number 09-166.0. Mice used for this study were
female C57BL/6 and A/J mice (Jackson Laboratory, Bar Harbor, ME)
between the ages of 6 and 8 weeks. All mice were housed in AAALAC-
accredited animal facilities with approved Public Health Service (PHS)
assurance.
Strains and media. Strains of Cryptococcus neoformans var. grubii used
in this study were KN99 (wild type) (30), CDX18 (gpr4 gpr5) (34, 45),
LHO31-1 (otc1) (32), and LHO17 (gpr4 GPR5). The LHO17 strain was
isolated from the progeny of matings between CDX18 and KN99a. Briefly,
matings were performed on V8 agar, and basidiospores were microma-
nipulated as previously described (20). The gpr4 GPR5 strain was iso-
lated using yeast extract-peptone-dextrose (YPD) agar containing 200
g/ml neomycin (NEO) and via a lack of growth on YPD agar containing
200 g/ml nourseothricin (NAT). Strains were then screened by PCR to
verify the presence of wild-type GPR5 and to determine the mating type.
All strains were stored in glycerol at 80°C and grown on YPD agar or in
YPD broth medium (BD Biosciences, Sparks, MD).
Growth assays. To assess whether the mutant strains had altered
growth phenotypes in vitro, liquid cultures of KN99, the gpr4 gpr5
strain, the complemented gpr4 GPR5 strain, and the otc1 strain were
inoculated and allowed to grow overnight in YPD. Stationary-phase cul-
tures were serially diluted 1:40 in phosphate-buffered saline (PBS; Lonza,
Rockland, ME) and then 1:50 in four different growth media: YPD,
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, Grand
Island, NY) supplemented with 10% fetal bovine serum (FBS; ATCC,
Manassas, VA), and L-DOPA medium with and without L-3,4-dihydroxy-
phenylalanine (DOPA). Two 96-well round-bottom plates were inocu-
lated with triplicate cultures of each strain in 150 l of each medium. Each
plate was incubated for 48 h with shaking in a Tecan Sunrise plate reader
(Tecan Group Ltd., Männedorf, Switzerland), and the absorbance at 595
nm was measured every 15 min. One plate was grown at 30°C, and one was
grown at 37°C. In vitro growth assays were performed twice, with similar
results. Additional growth assays were performed in which 1  106 cells of
each strain were serially diluted, spotted onto YPD medium, and grown at
either 30°C or 37°C.
To assess in vivo replication, C. neoformans cells were cultured over-
night in YPD broth. The resulting yeast cells were labeled with Alexa Fluor
488 (AF488) or Alexa Fluor 594 (AF594) (Invitrogen, Grand Island, NY)
as described previously (33), pelleted, and resuspended in sterile PBS at a
concentration of 1  108 cells/ml, based on hemacytometer counts.
Groups of 6- to 8-week-old female C57BL/6 mice were anesthetized by
intraperitoneal pentobarbital injection. Three to five mice per treatment
were infected intranasally with 5  106 cells in 50 l PBS. At 3 days
postinfection, mice were sacrificed by CO2 inhalation. Lungs were sub-
jected to lavage with 1.5 ml sterile PBS three times, using an 18.5-gauge
needle placed in the trachea. Cells in the lavage fluid were pelleted at
16,000  g, resuspended in 3.7% formaldehyde, and incubated at room
temperature for 30 min. Cells were then washed once with PBS, and
2,000 cells per animal were examined by microscopy (AxioImager; Carl
Zeiss, Inc.). Ratios of stained cells (original inoculum) to unstained cells
(nascent cells) were used to calculate in vivo doubling times.
To assess whether mutant strains have altered growth in whole blood,
C57BL/6 mice were euthanized by CO2 inhalation. Whole blood was col-
lected by cardiac puncture, and heparin sodium (Sigma, St. Louis, MO)
was added as an anticoagulant to a final concentration of 50 g/ml of
blood. KN99 (wild-type) and CDX18 (gpr4 gpr5) cells were cultured
overnight on YPD agar. The resulting yeast cells were resuspended in
sterile PBS to a concentration of 1  106 cells/ml by hemacytometer
count. A total of 1  104 cells were added to 100 l whole blood with 50
g/ml heparin sodium, YPD broth with 50 g/ml heparin sodium, or
YPD broth. Samples were incubated for 24 h at 37°C and 5% CO2. Serial
dilutions were plated on YPD agar for CFU enumeration.
Analysis of virulence factor production. The gpr4 gpr5 and otc1
mutant strains as well as the wild-type KN99 strain were grown over-
night in YPD broth at 30°C. Ten microliters of each culture was spotted
onto Christensen’s urea agar medium (13) or L-DOPA medium (12) to
test urease or melanin production, respectively. Plates were incubated at
30°C and monitored daily for a pH change (Christensen’s urea medium)
or melanin pigmentation (L-DOPA medium). In addition, urease, mela-
nin, and in vitro capsule production was quantified following broth cul-
ture by use of an H1 Synergy plate reader (BioTek Instruments Inc., Win-
ooski, VT). Samples were prepared as described above for growth assays,
with the inclusion of Christensen’s urea medium, and the absorbances at
560 nm (urease) and 350 nm (melanin) were determined. In vitro capsule
production was measured using a Premier cryptococcal antigen kit (Me-
ridian Bioscience, Cincinnati, OH). Capsule production was also analyzed
in vivo. Briefly, cells were cultured overnight in YPD broth, pelleted, and
resuspended in sterile PBS, and mice were infected intranasally with 5 
106 cells in 50 l PBS. At 3 days postinfection, mice were sacrificed by CO2
inhalation. Lungs were subjected to lavage, cells in the lavage fluid were
fixed and stained with India ink, and the capsule was observed by micros-
copy.
Purified titan and normal-size cells. KN99 and KN99a cells were
cultured overnight in YPD broth. The resulting yeast cells were pelleted
and resuspended in sterile PBS. To harvest titan cells, A/J or C57BL/6 mice
were anesthetized by intraperitoneal pentobarbital injection and infected
intranasally with 5  106 KN99 cells, or a 1:1 ratio of KN99 and KN99a
cells to stimulate titan cell production, in 50 l PBS. At 3 or 5 days postin-
fection, mice were sacrificed by CO2 inhalation and lungs subjected to
lavage as described above. Cells in the bronchoalveolar lavage (BAL) fluid
were pelleted, resuspended in 0.05% SDS in sterile water for 1 min to
promote host cell lysis, pelleted, and resuspended in PBS. Titan and nor-
mal-size cells were purified using fluorescence-activated cell sorting
(FACS) or by filtration. For FACS, cells were sorted based on size, using an
iCyt Reflection flow cytometer (iCyt, Champaign, IL). Because capsule
size differences can affect cell size analysis by forward scatter during flow
cytometry, normal-size cells were classified as those with a cell body di-
ameter of 10 m, and titan cells were classified as those with a cell body
diameter of 15 m. After sorting, the titan cell population had 97%
purity and the normal-size cell population had 90% purity. For filtra-
tion purification, titan cells were isolated by filtration through a 20-m
CellMicroSieve (BioDesign, New York, NY), concentrated by centrifuga-
tion, and resuspended in sterile PBS. Normal-size cells that passed
through the filter were concentrated by centrifugation and resuspended in
sterile PBS. To infect mice with the purified cell populations, groups of A/J
or C57BL/6 mice were anesthetized and infected intranasally with 1  103
or 1  104 purified titan or normal-size cells in 25 or 50 l of PBS. Mice
were sacrificed at 3, 5, and 7 days postinfection. Lungs from each animal
were homogenized in 1 or 4 ml PBS, and serial dilutions were plated on
YPD agar for CFU enumeration.
Survival assay. Ten C57BL/6 mice per group were anesthetized and
inoculated intranasally with 1  103 wild-type KN99, gpr4 gpr5, or
gpr4 GPR5 cells suspended in 50 l PBS. Animals were monitored for
morbidity and sacrificed when endpoint criteria were reached. Endpoint
criteria were defined as 20% total body weight loss, loss of 2 grams of
weight in 2 days, or symptoms of neurological damage. Tissues (lung and
brain) were collected from a subset of animals to determine fungal bur-
dens at the time of sacrifice. Mice that survived to 62 days postinfection
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without exhibiting signs of disease were sacrificed and their tissues pro-
cessed as described above for determination of fungal burdens.
In vivo growth kinetics. Overnight broth cultures of wild-type
KN99, gpr4 gpr5, or otc1 cells were pelleted, washed with sterile
PBS, and resuspended to 2  104 cells/ml based on hemacytometer
counts. Eight C57BL/6 mice per strain per time point were anesthetized,
and 1  103 cells in 50 l of inoculum was administered intranasally. Mice
were sacrificed either at 0, 6, 14, 24, and 30 h postinfection or at 0, 5, 7, 14,
and 21 days postinfection. Lungs, spleens, and brains were collected in 1
ml sterile PBS, homogenized, and plated on YPD agar supplemented with
chloramphenicol for enumerating CFU.
Intracerebral infections. Animals were deeply anesthetized by intra-
peritoneal injection of pentobarbital. Eight C57BL/6 mice per group were
infected intracerebrally with 1  103 fungal cells in 20 l PBS injected
slowly into the top of the cerebrum. At 4 days postinfection, animals were
sacrificed, and brains were collected, processed as described above, and
plated for CFU.
Phagocytosis viability assay. Cryptococcal cells were fluorescently la-
beled using an Alexa Fluor 488 protein labeling kit (Invitrogen, Eugene,
OR) as described above. C57BL/6 mice were anesthetized and inoculated
intranasally with 5  106 labeled cells in 50 l PBS. At 24 h postinfection,
mice were sacrificed and BAL was performed. Three or four lavage fluid
samples were pooled, pelleted at 376  g for 5 min, resuspended in 100 l
FACSBuffer (PBS plus 2% fetal bovine serum), and stained with anti-
CD45–allophycocyanin (APC) (BioLegend, San Diego, CA) at a 1:100
dilution. Cells were stained on ice in the dark for 30 min, washed three
times with FACSBuffer, and resuspended in FACSBuffer for sorting on a
FACS Aria II flow cytometer (BD Biosciences, Sparks, MD). Double-pos-
itive (AF488 APC) cells were defined as phagocytosed cryptococcal
cells, and single-positive (AF488 APC) cells were defined as extracel-
lular cryptococcal cells. After sorting, the cell number collected by the
FACS Aria II instrument was recorded, and serial dilutions were plated on
YPD agar to assess viability. For a subset of studies, the cell number col-
lected during sorting was verified by hemacytometer counts. Percent sur-
vival was calculated by dividing the number of CFU by the total number of
cells plated for each sample.
Lung leukocyte isolation. Lung leukocytes were isolated as described
previously (47). Briefly, lungs were excised, placed in Hanks balanced salt
solution (HBSS) with 1.3 mM EDTA, and minced to generate approxi-
mately 1-mm3 pieces. The lung mince was then incubated in the HBSS–
1.3 mM EDTA solution for 30 min at 37°C with agitation. The cells were
pelleted, resuspended in RPMI medium supplemented with 5% FBS and
150 U/ml type I collagenase (Invitrogen, Grand Island, NY), and incu-
bated for 1 h at 37°C with agitation. The cells were passed through a
70-m filter, pelleted, resuspended in 44% Percoll-RPMI medium (GE
Life Sciences, Pittsburgh, PA), and added to a Percoll density gradient
(44% top, 67% bottom), and the samples were centrifuged for 20 min at
650  g. The leukocytes at the interface were removed, washed 2 times
with 10 ml of RPMI medium, and resuspended in medium at a concen-
tration of 107 cells/ml.
Leukocytes were processed for flow cytometry by treatment with
CD16/32 antibody to block the FC receptor and prevent nonspecific an-
tibody binding. Cells were stained with Siglec-F–phycoerythrin (BD Bio-
sciences, San Jose, CA), IgE-fluorescein isothiocyanate, Ly6G-allophyco-
cyanin-eFluor 780, and phycoerythrin-cyanine 5 (eBiosciences, San
Diego, CA) at a 1:100 dilution. For data acquisition, 250,000 events were
collected on a BD FACSCanto II flow cytometer (BD Biosciences, San
Jose, CA), and the data were analyzed with FlowJo 8.7 (Tree Star Inc.,
Ashland, OR).
Eosinophils were identified as described previously (41, 48), with the
following modifications. Live cells were gated based on forward and side
scatter properties. Eosinophils were identified as Siglec-F-positive, IgE-
negative, Ly6G-intermediate, and CD11c-negative cells. Figure S4 in the
supplemental material depicts the gating strategy used to identify and
quantify the eosinophil population.
Statistical analysis. All statistical analyses were performed using
GraphPad Prism (GraphPad Software, Inc., San Diego, CA) or Analyze-It
(Analyze-It, Ltd., Leeds, United Kingdom). The Mann-Whitney U test
was used to analyze survival, intracerebral infections, phagocytosis viabil-
ity assays, and brain and lung CFU from survival assays. One-way analysis
of variance (ANOVA) was used to analyze differences in doubling times.
Two-way ANOVA was used to analyze in vivo growth curves for the lung,
spleen, and brain. P values of 0.05 were considered significant.
RESULTS
Purified titan cells accumulate faster than normal-size cells dur-
ing early pulmonary infection. Titan cells are generated in re-
sponse to the pulmonary environment and have characteristics
that may promote their survival (32, 33, 46). These observations
suggest that titan cell production may provide a growth advantage
during establishment of pulmonary infection. To test this hypoth-
esis, FACS and filtration were used to purify wild-type titan or
normal-size cells from in vivo samples. The purified populations
were enriched 90% by FACS or filtration. Control infections
with normal-size cells grown in vitro or isolated from in vivo sam-
ples by FACS or filtration showed no differences in fungal burdens
measured by CFU at 3, 5, or 7 days postinfection, showing that
FACS did not alter the viability of the cells (data not shown).
Mice infected with purified titan cells had higher CFU at 3 and
5 days postinfection than did mice infected with purified normal-
size cells (Fig. 1). At 3 days postinfection, mice infected with pu-
rified titan cells had a significant increase in fungal burden com-
FIG 1 Infections with purified titan cells result in larger lung fungal burdens.
(A) A/J mice were infected intranasally with 1  104 wild-type (KN99) titan
or normal-size cells purified by cell sorting. (B) C57BL/6 mice were infected
intranasally with 1  103 wild-type (KN99) titan or normal-size cells purified
by filtration. Lungs were extracted at 3 and 5 days postinfection and homoge-
nized, and serial dilutions were plated to determine tissue burdens. Error bars
indicate standard deviations for 4 or 5 mice per time point.
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pared to mice infected with normal-size cells (Fig. 1) (P 	 0.015
and P 	 0.0079 for mice infected with 1  104 cells and 1  103
cells, respectively). This increase in fungal burden was still signif-
icant at 5 days postinfection for mice infected with 1  104 cells
(Fig. 1A) (P 	 0.043) but was no longer statistically significant for
mice infected with 1  103 cells (Fig. 1B) (P 	 0.29). These data
indicate that titan cells can provide a growth advantage during
establishment of pulmonary infection.
By 7 days postinfection, equivalent CFU were observed in mice
infected with purified titan cells or normal-size cells at both the
higher and lower inoculums (P 	 0.89 and P 	 0.56, respectively)
(data not shown). Previous studies showed that normal-size cryp-
tococcal cells can develop into titan cells within 24 h and that titan
cells generate normal-size cells upon budding (33, 46). Analysis of
the cryptococcal cells in the lungs of mice infected with the puri-
fied cell populations at 7 days postinfection revealed a mixture of
both normal-size and titan cells (data not shown). Thus, the pu-
rified populations were not maintained over time, and the long-
term effects on fungal burden due to titan cell production could
not be determined using these FACS- or filter-purified cell popu-
lations.
Titan cell production enhances virulence in murine survival
assays. To determine the long-term effects of titan cell formation
on the virulence of C. neoformans, a system in which the titan cell
and normal-size cell states were maintained over time was needed.
A targeted mutant screen was performed to identify genes in-
volved in titan cell development that did not alter other traits
known to affect virulence (34). This screen showed that the gpr4
gpr5 mutant, which lacks both the Gpr4 and Gpr5 receptors,
important for environmental sensing, had significantly reduced
titan cell formation (34, 45). While the wild-type strain exhibited
20% titan cell production at 72 h postinfection, the gpr5 and
gpr4 gpr5 mutant strains exhibited 3% and 1% titan cell for-
mation, respectively (32, 34). Deletion of GPR4 alone (gpr4) did
not affect titan cell production, but lack of this gene further re-
duced titan cell production in the gpr4 gpr5 mutant (32, 34).
Complementation of the GPR5 gene restored titan cell formation
in the gpr4 GPR5 strain to wild-type levels (32, 34).
To utilize the gpr4 gpr5 strain in assays to determine the
effect of titan cell production on cryptococcal survival and viru-
lence in the host, we determined whether the gpr4 gpr5 strain
had altered production of other factors known to affect virulence.
The gpr4 gpr5 strain exhibited wild-type growth and cell size in
DMEM, minimal medium, and rich medium, at both 30°C and
37°C (see Fig. S1 in the supplemental material; also data not
shown). In addition, the in vivo replication rates for the wild-type
and gpr4 gpr5 strains were determined by monitoring cell di-
vision of fluorescently labeled cells and quantifying the propor-
tion of the population that was no longer fluorescent (see Table
S1). The in vivo replication rates for the wild-type and gpr4 gpr5
strains were equivalent (P 	 0.44). Finally, the gpr4 gpr5 strain
expressed wild-type levels of other virulence factors, including
capsule, melanin, and urease (see Fig. S2; also data not shown).
Thus, the gpr4 and gpr5 mutations do not have global effects on
virulence factor production. While we cannot rule out the possi-
bility that the gpr4 gpr5 strain has a defect in an as yet unchar-
acterized phenotype important for virulence, the mutations ap-
pear to affect titan cell production only.
The gpr4 gpr5 strain, with limited titan cell production, was
used to assess the long-term effect of titan cell production on the
survival and proliferation of C. neoformans in the murine inhala-
tional model of cryptococcosis. We hypothesized that titan cell
production would promote C. neoformans virulence and that the
gpr4 gpr5 strain, with reduced titan cell production, would
have attenuated virulence. To test this hypothesis, mice were in-
fected intranasally with the wild-type, gpr4 gpr5, or comple-
mented gpr4 GPR5 strain and monitored for signs of morbidity
(Fig. 2). All mice infected with the wild-type strain succumbed to
the infection between 21 and 27 days postinfection (Fig. 2). In
contrast, mice infected with the gpr4 gpr5 mutant strain did not
exhibit morbidity until 28 days postinfection, and only 40% of
mice succumbed to the infection by 61 days postinfection (Fig. 2)
(P 	 0.0001). The complemented gpr4 GPR5 strain had viru-
lence equivalent to that of the wild-type strain in this survival assay
(Fig. 2) (P 	 0.53). Thus, the attenuated virulence observed in the
gpr4 gpr5 strain was due to deletion of the GPR5 gene.
Mice that succumbed to the gpr4 gpr5 infection exhibited
lower fungal burdens in the lungs than those of mice infected with
the wild-type strain, whereas fungal burdens in the brain were
equivalent between the two strains (Fig. 3) (P 	 0.036 and P 	
0.79, respectively). These data show that the 40% mortality ob-
served with the gpr4 gpr5 infections was due to central nervous
system (CNS) disease. Mice that did not succumb to the gpr4
gpr5 infection by 62 days postinfection had low lung and brain
fungal burdens (Fig. 4), suggesting that 60% of the mice had con-
trolled the gpr4 gpr5 infection. Taken together, these data show
that reduced titan cell formation resulted in attenuated virulence.
Titan cell production enhances pulmonary survival and pro-
liferation. The initial site of cryptococcal infection is the lungs.
Based on infections with wild-type purified titan cell populations,
we hypothesized that titan cells may promote establishment of the
pulmonary infection. Therefore, we determined the effects of titan
cell production on the pulmonary fungal burden by using the
gpr4 gpr5 mutant strain. Mice were infected intranasally with
wild-type or gpr4 gpr5 cells, and CFU in the lungs were deter-
mined at 0, 6, 14, 24, and 30 h as well as at 5, 7, 14, and 21 days
postinfection (Fig. 5). Both the wild-type and gpr4 gpr5 strains
had lower CFU in the lungs at 6 h postinfection than at the base-
line (0 h) time point (Fig. 5A), suggesting cryptococcal cell death
upon exposure to the pulmonary environment. While the differ-
ence in fungal burdens at 6 h was not statistically significant, the
trend was consistent between multiple experiments. The gpr4
gpr5 mutant strain, lacking titan cell production, exhibited re-
FIG 2 Titan cell production enhances virulence of C. neoformans. Groups of
10 C57BL/6 mice were infected intranasally with 1  103 wild-type (KN99;
WT), gpr4 gpr5, or gpr4 GPR5 cells, and progression to severe morbidity
was monitored for 62 days.
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duced fungal burdens compared to those of the wild-type strain by
30 h postinfection (Fig. 5A). This trend continued throughout the
infection. By 21 days postinfection, the gpr4 gpr5 mutant strain
had a 10-fold reduction in CFU compared to the wild-type strain
(Fig. 5B) (P 	 0.001). The observation that lower fungal burdens
were seen in the absence of titan cell production suggests that
production of titan cells promotes survival and proliferation of
cryptococcal cells in the pulmonary environment.
Consistent with these findings, an otc1 mutant that overpro-
duces titan cells (32) had enhanced survival in the pulmonary
environment (see Fig. S3 in the supplemental material). The otc1
strain has a mutation in the OTC1 gene, encoding a protein of
unknown function (32). Similar to the gpr4 gpr5 strain, the
otc1 strain exhibited wild-type in vitro growth and expression of
other factors important for virulence (see Fig. S1 and S2; also data
not shown). However, the otc1 strain had impaired in vivo rep-
lication (see Table S1). Even in the absence of in vivo replication,
the titan cell-overproducing otc1 strain resisted the initial cell
death observed in the wild-type and gpr4 gpr5 strains (data not
shown). In addition, the otc1 titan cells persisted in the lungs for
at least 62 days postinfection (see Fig. S3B). No dissemination of
the otc1 mutant strain overproducing titan cells was observed
(see Fig. S3C). These data suggest that titan cell production can
promote cryptococcal cell survival upon exposure to the pulmo-
nary environment, even in the absence of cell division.
Titan cell production inhibits phagocytosis to promote C.
neoformans survival. Phagocytosis by resident alveolar macro-
phages is one of the first lines of defense utilized by the innate
immune system to control pulmonary infections (4). Previous
studies have shown that titan cells are resistant to phagocytosis
and that titan cell production significantly decreases the pulmo-
nary phagocytosis rate of C. neoformans (32, 33). The data pre-
sented above show that titan cell production resulted in increased
FIG 3 Fungal burdens in mice that succumbed to infection with wild-type or
gpr4 gpr5 strain. C57BL/6 mice were infected intranasally with 1  103
wild-type (KN99) or gpr4 gpr5 cells, monitored for disease morbidity, and
sacrificed when endpoint morbidity criteria were reached. Lungs (A) and
brains (B) were harvested and homogenized, and serial dilutions were plated
for CFU determinations. Error bars indicate standard deviations for 3 to 5
mice per treatment group.
FIG 4 Fungal burdens in mice that survived infection with the gpr4 gpr5
strain. C57BL/6 mice were infected intranasally with 1  103 gpr4 gpr5 cells
and monitored for 62 days. Those animals that survived to 62 days without
signs of disease morbidity were sacrificed, lungs (A) and brains (B) were har-
vested and homogenized, and serial dilutions were plated for CFU determina-
tions. Error bars indicate standard deviations for 5 mice.
FIG 5 Titan cell production enhances survival and proliferation in the pul-
monary environment. C57BL/6 mice were infected intranasally with 1  103
wild-type (KN99) or gpr4 gpr5 cells. At 0, 6, 14, 24, and 30 h postinfection
(A) or 0, 5, 7, 14, and 21 days postinfection (B), lungs were harvested and
homogenized, and serial dilutions were plated to determine tissue burdens.
Fungal burdens are expressed as percentages relative to the level at 0 h postin-
fection. Error bars represent standard deviations for 7 or 8 mice per strain per
time point.
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fungal burdens in the lungs, suggesting that reduced phagocytosis
may lead to increased cellular survival.
To test this hypothesis, the viability of in vivo phagocytosed
and extracellular cryptococcal cells was determined. Mice were
infected intranasally with wild-type or gpr4 gpr5 cells that had
been fluorescently labeled with Alexa Fluor 488 to allow for detec-
tion and sorting of the cryptococcal cells. At 24 h postinfection,
bronchoalveolar lavages were performed, and samples were
stained with anti-CD45–APC to label all phagocytes. Samples
were then sorted by FACS, and both phagocytosed cryptococcal
cells (AF488 CD45-APC) and extracellular cryptococcal cells
(AF488 CD45-APC) were collected. The total cell number in
each population was determined during sorting and verified by
hemacytometer counting for a subset of samples. The viability of
the FACS-sorted populations was determined by comparison of
CFU to the total number of cells plated. For the wild-type infec-
tions, the viability of the phagocytosed population (12.4%) was
significantly lower than the viability of the extracellular popula-
tion (34.7%) (Fig. 6) (P 	 0.0022). A similar trend was observed
with the gpr4 gpr5 strain, which has limited titan cell produc-
tion (P 	 0.0012) (data not shown). These results show that
phagocytosis of C. neoformans in vivo results in decreased cell vi-
ability and suggest that reduced phagocytosis in the presence of
titan cells decreases killing by phagocytes to promote pulmonary
survival.
Titan cell production enhances dissemination of C. neofor-
mans. The time course data presented above show that titan cell
production promotes survival and proliferation of cryptococcal
cells in the pulmonary environment due to decreased phagocyto-
sis. Yet the primary site of disease during cryptococcal infections is
the central nervous system (5, 19). Thus, the effect of titan cell
production on hematogenous dissemination as well as penetra-
tion and replication in the brain was determined.
The number of CFU present in the spleen was used as a mea-
sure of the ability of the wild-type and gpr4 gpr5 strains to
spread hematogenously to other organs. Both the wild-type and
gpr4 gpr5 strains had no detectable dissemination to the spleen
at 7 days postinfection (Fig. 7A). At 14 days postinfection, lower
fungal burdens in the spleen were observed for the gpr4 gpr5
mutant strain than for the wild type (Fig. 7A). By 21 days postin-
fection, the gpr4 gpr5 mutant strain had a 100-fold reduction in
CFU compared to the wild-type strain (Fig. 7A) (P 	 0.01). These
data show that hematogenous dissemination from the lungs is
severely impaired in the absence of titan cell production.
Fungal burdens in the brain were also markedly reduced in
mice infected with the gpr4 gpr5 mutant strain compared to
those infected with the wild type (Fig. 7B). Dissemination of the
gpr4 gpr5 mutant to the brain was higher than that of the wild
type at 7 days postinfection, although the difference was not sta-
tistically significant (Fig. 7B) (P 	 0.18). By 21 days postinfection,
the gpr4 gpr5 mutant strain exhibited a 300-fold decrease in
FIG 6 Extracellular cryptococcal cells have higher viability than phagocytosed
cells. C57BL/6 mice were infected intranasally with 5  106 KN99 or gpr4
gpr5 cells labeled with Alexa Fluor 488, and BAL was performed at 24 h
postinfection. BAL fluid samples from 3 or 4 mice were pooled, stained with
anti-CD45–APC, and sorted for intracellular cryptococcal cells (AF488
APC; Phag.) or extracellular cryptococcal cells (AF488 APC; Extrac.). The
cell concentration after sorting was determined by hemacytometer counts.
Cells were plated for viability on YPD medium. Error bars represent standard
errors for 2 experiments with 3 or 4 replicate pools.
FIG 7 Titan cell production increases dissemination from the lungs. (A and B)
C57BL/6 mice were infected intranasally with 1  103 wild-type (KN99) or
gpr4 gpr5 cells. At 0, 5, 7, 14, and 21 days postinfection, spleens (A) and
brains (B) were harvested and homogenized, and serial dilutions were plated
for CFU determinations. Error bars represent standard deviations for 7 or 8
mice per strain per time point. (C) C57BL/6 mice were inoculated intracere-
brally with 1  103 wild-type (KN99) or gpr4 gpr5 cells. At 4 days postin-
oculation, animals were sacrificed, brains were extracted and homogenized,
and serial dilutions were plated for CFU determinations. Error bars indicate
standard deviations for 8 mice per treatment group.
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brain fungal burden compared to that in mice infected with the
wild-type strain (Fig. 7B) (P 	 0.001).
The difference between wild-type and gpr4 gpr5 cell accu-
mulation in the brain could be due to reduced survival of the
gpr4 gpr5 strain in blood, reduced growth of the gpr4 gpr5
strain within the brain, or reduced dissemination of the gpr4
gpr5 strain. The gpr4 gpr5 and wild-type strains had equiva-
lent growth in whole blood (see Fig. S1B in the supplemental
material). To examine growth within the brain, mice were infected
intracerebrally and CFU were determined at 4 days postinfection.
No difference in brain fungal burdens between the gpr4 gpr5
and wild-type strains was observed for intracerebral infections
(Fig. 7C) (P 	 0.16). Thus, the wild-type and gpr4 gpr5 cells
grew equally well in the brain, indicating that the low fungal bur-
dens observed with gpr4 gpr5 infection were due to reduced
dissemination in the absence of titan cell production.
Titan cell production alters the host immune response. The
observation that titan cells enhance multiple aspects of the cryp-
tococcal infectious process, such as growth in the pulmonary en-
vironment and dissemination, led us to hypothesize that titan cells
are capable of altering the host immune response to promote dis-
ease progression. Since eosinophils are recruited to the lung dur-
ing wild-type infection (36) and play a pathological role in the
immune response to C. neoformans (21), we compared eosinophil
quantities in the lung 14 days after infection with the wild-type
strain, which is capable of titan cell production, or the gpr4
gpr5 strain, which has minimal titan cell production. Lungs of
mice infected with wild-type Cryptococcus had larger numbers of
eosinophils than did lungs of mice infected with the gpr4 gpr5
strain (Fig. 8B) (P 	 0.0256). In addition, eosinophils accounted
for a larger proportion of the host pulmonary immune cell popu-
lation in mice infected with the wild-type than in those infected
with the gpr4 gpr5 strain (Fig. 8A) (P 	 0.0013). Therefore,
titan cell production is a potential mechanism that Cryptococcus
employs to alter host immune responses.
DISCUSSION
Virulence factors are phenotypes associated with organisms that
promote their pathogenesis. Typically, virulence factors are de-
fined by three criteria: (i) the phenotype is expressed in vivo, (ii)
the phenotype alters host-pathogen interactions, and (iii) disrup-
tion of the phenotype results in altered virulence (17). Titan cells
are generated by C. neoformans in response to the in vivo pulmo-
nary environment, and their production is regulated by the same
signal transduction pathway that regulates other known virulence
factors (33, 34, 46). The large size of titan cells inhibits phagocy-
tosis by host cells (32, 33, 46). In addition, titan cells exhibit aber-
rant binding by complement, which likely results in an alteration
in the complement-induced host response (46). Titan cells also
have characteristics that promote their survival in the host, such as
resistance to oxidative/nitrosative stress and structural changes in
the capsule and cell wall (33, 46). Thus, titan cells have altered
host-pathogen interactions. Using both purified cell populations
and mutants with disrupted titan cell production, we show here
that titan cell production promotes survival and proliferation in
the lungs and dissemination to the brain and ultimately results in
enhanced virulence compared to that of a mutant strain lacking
titan cell formation. These data unequivocally show that titan cell
production has all the hallmarks of a novel virulence factor gen-
erated by C. neoformans to promote virulence.
Titan cell production is observed predominantly in the
lungs and is readily apparent in experimentally infected mice
by 24 h postinfection (33). Mice infected with purified titan
cells exhibited increased fungal burdens at early time points,
showing that titan cells can promote establishment of pulmo-
nary infection. Interestingly, the effect of titan cell production
on early pulmonary infections was more pronounced when
mice were infected with purified titan cells than when they were
infected with mutant strains with altered titan cell formation.
These differences were likely due to intrinsic differences in cells
of the infecting inoculum because of cell size or tolerance to the
host environment.
Resident alveolar macrophages phagocytose and kill inhaled
pathogens, but titan cells are too large to be phagocytosed (32, 33).
Because titan cells themselves are protected from phagocytosis
due to their size (32), the vast majority of the cells in the purified
titan cell inoculum would survive the initial host phagocytic im-
mune response, resulting in increased survival. To generate puri-
fied cell populations, the cells were passaged in mice to stimulate
titan cell production. Thus, the purified cell populations were al-
ready acclimated to the host environment. The 10-fold increase in
fungal burden in infections with purified titan cells compared to
those with purified normal-size cells was likely due to the inability
of the resident alveolar macrophages to phagocytose and kill the
titan cells. The effect of previous exposure to the host environ-
ment was minimized by using purified normal-size cells that had
also been passaged through mice.
In contrast, the gpr4 gpr5 mutant and wild-type strain in-
FIG 8 Titan cell production increases eosinophil accumulation in the
lungs. Groups of C57BL/6 mice were infected intranasally with 5  104
wild-type (KN99) or gpr4 gpr5 cells. Lungs were harvested at 14 days
postinfection for enumeration of eosinophils. The proportion of total leu-
kocytes (A) and number of cells per lung (B) that were Siglec-F IgE
Ly6Gint CD11clow are represented. Error bars indicate standard deviations
for 4 to 7 mice per group.
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oculums were grown in vitro. Not only were all of the cells in the
infecting inoculums of a normal size, but also the cells were not
acclimatized to the host environment. The wild-type and gpr4
gpr5 strains exhibited equivalent early cell death upon exposure
to the pulmonary environment. The similarity between the wild-
type and gpr4 gpr5 cell survival rates could be because the cells
were not acclimatized to the host environment. The low level of
titan cell production in the wild-type strain at early time points
may be insufficient to protect the majority of cells in the inoculum
from phagocytosis by resident alveolar macrophages. Instead,
protection from phagocytosis for the wild-type strain may have a
larger impact later in the infection, when additional phagocytic
cells are recruited to the lungs.
Our viability data show that in early lung infections, it is not
beneficial for C. neoformans to be phagocytosed. Increased phago-
cytosis of the gpr4 gpr5 strain at early stages of infection was
correlated with lower fungal burdens at later times during infec-
tion. These data suggest that an intracellular lifestyle is less con-
ducive to growth and survival of C. neoformans than an extracel-
lular lifestyle. There are common features that distinguish
extracellular pathogens from intracellular pathogens. Extracellu-
lar pathogens employ mechanisms to prevent phagocytosis, are
capable of extracellular replication, and are generally thought to
prime a humoral immune response. For example, the extracellular
pathogen Streptococcus pyogenes produces a capsule of hyaluronic
acid that aids in prevention of phagocytosis and antibody-me-
diated opsonization, which is an essential component of pro-
tective immunity against S. pyogenes (42). Conversely, intracel-
lular pathogens actively stimulate uptake into host cells and utilize
mechanisms for intracellular survival and replication, and their
clearance requires induction of a cell-mediated immune response.
For example, the intracellular pathogen Listeria monocytogenes es-
capes the phagolysosome by using the protein listeriolysin O,
allowing L. monocytogenes to survive and replicate in the cytoplas-
mic space of the host cell. L. monocytogenes also produces interna-
lins that stimulate entry into host cells (14).
C. neoformans, being a facultative intracellular pathogen, ex-
hibits characteristics of both extracellular and intracellular micro-
organisms. Like S. pyogenes, C. neoformans induces production of
an antiphagocytic capsule in vivo (19). Uptake of cryptococcal
cells into phagocytes is not actively induced by cryptococcal fac-
tors but rather is due to recognition and subsequent uptake by the
phagocyte (19). Once inside the phagolysosome, C. neoformans
can actively extrude itself from the cell into the extracellular space
by nonlytic exocytosis, or vomocytosis (2, 3, 25). Yet, like intra-
cellular pathogens, once C. neoformans is taken up by a host
phagocyte, it induces production of a large variety of genes that
allow for intracellular survival in the phagolysosome (18).
While Cryptococcus is able to survive both intracellularly and
extracellularly, it appears that titan cell production promotes the
extracellular lifestyle by prevention of phagocytosis. The protec-
tion from phagocytosis by titan cell production occurs in at least
two ways. Titan cells themselves are intrinsically protected from
phagocytosis due to their large size (32, 33). Yet titan cell produc-
tion also has a global effect, because normal-size cells are protected
from phagocytosis when titan cells are present (32). This shift
toward an extracellular lifestyle aids in better cryptococcal cell
survival in the early stages of infection, which is likely essential for
establishment of the infection. In addition, the observation that
otc1 cells are not cleared from the lungs for at least 2 months
suggests that the host immune response is unable to efficiently kill
extracellular titan cells.
The viability of phagocytosed cryptococcal cells was decreased
compared to that of extracellular cryptococcal cells. This was
somewhat surprising given the evidence that at later stages of in-
fection, intracellular C. neoformans promotes dissemination to the
CNS (11, 15, 24). These studies create a paradox where in one case
an intracellular lifestyle leads to reduced cell viability and is nega-
tively correlated with virulence and in the other case an intracel-
lular lifestyle promotes disease by increasing dissemination to the
CNS. Our studies examined phagocytosis at early stages of infec-
tion. It is possible that in later stages of the infection, the immune
environment is altered such that it is more permissive for intra-
cellular survival and replication. The observation that titan cell
production increases the number and proportion of eosinophils
in the lungs supports this hypothesis. Eosinophils are typically
produced in response to extracellular pathogens and are charac-
teristic of TH2-type immune responses, where a classical phago-
cytic response is not as protective. As the cryptococcal infection
progresses, changes in the cell types present in the lungs or the
activation state of the alveolar macrophages could shift from a
classically activated fungicidal state toward an alternatively acti-
vated state that is more permissive for intracellular growth. An
alternative hypothesis is that fitness of the cryptococcal cells them-
selves could change over the course of infection. As the cryptococ-
cal cells continue to adapt to the host environment, they may
develop better tolerance for the intracellular lifestyle. Previous
studies have shown that cryptococcal cells upregulate a number of
genes whose protein products are important for survival within
macrophages upon phagocytosis in vitro (18).
Intracellular cryptococcal cells have increased dissemination to
the CNS compared to extracellular cells (11). Thus, the effect that
titan cell production had on dissemination of C. neoformans to the
CNS was surprising. In the absence of titan cells, we anticipated
that increased phagocytosis would result in increased dissemina-
tion. This could be true, as the gpr4 gpr5 mutant cells were
detected in the brain earlier than the wild-type cells. However, the
overall dissemination was much lower for the gpr4 gpr5 mutant
than for the wild type. These data suggest that other effects of titan
cell production, beyond simply limiting phagocytosis, alter dis-
semination from the lungs.
Unfortunately, because the otc1 mutant strain had a replica-
tion defect in vivo, we were unable to determine the long-term
effect of titan cell overproduction on cryptococcal virulence. Pre-
vious studies which overproduced titan cells through stimulation
of pheromone signaling showed decreased CNS penetration (29).
The fact that no dissemination of the otc1 mutant strain was
observed provides further support that titan cells themselves may
not be able to exit the lungs. Even though the otc1 titan cells did
not disseminate, the cells were able to persist in the lungs for a
minimum of 2 months. Thus, titan cell production may also play
a key role in the development of dormant or persistent infections.
Evidence suggests that dormant cryptococcal infections that de-
velop in healthy individuals can reactivate upon failure of the im-
mune system (16).
Titan cell production is involved in promoting cryptococcal
cell survival, proliferation, and dissemination. Thus, titan cell pro-
duction plays a key role in cryptococcal virulence and could be a
novel target for treatment strategies aimed at reducing infection
rates or dissemination in immunocompromised patient popula-
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tions. Drug treatments that target developmental or morpholog-
ical stages important for pathogenesis have been developed for
other eukaryotic parasites. In malaria, some drugs target schizonts
while other drugs target gametocytes (44). Similarly, drugs that
target microfilaria dramatically reduced canine heartworm infec-
tions by Dirofilaria immitis (27). If similar treatment strategies
targeting titan cells are developed for C. neoformans, the incidence
of these infections and their impact could be reduced dramati-
cally.
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